IRIDEX Corporation (IRIX)vsJohnson & Johnson (JNJ)
IRIX
IRIDEX Corporation
$1.03
0.00%
HEALTHCARE · Cap: $18.69M
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 182837% more annual revenue ($96.36B vs $52.67M). JNJ leads profitability with a 21.8% profit margin vs -8.4%. IRIX appears more attractively valued with a PEG of 0.94. JNJ earns a higher WallStSmart Score of 59/100 (C).
IRIX
Hold38
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+82.1%
Fair Value
$8.00
Current Price
$1.03
$6.97 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
16.0% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -126.4% — below average capital efficiency
Currently unprofitable
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRIX
The strongest argument for IRIX centers on PEG Ratio, Revenue Growth. Revenue growth of 16.0% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : IRIX
The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
IRIX profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
IRIX carries more volatility with a beta of 0.76 — expect wider price swings.
IRIX is growing revenue faster at 16.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 38/100), backed by strong 21.8% margins. IRIX offers better value entry with a 82.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IRIDEX Corporation
HEALTHCARE · MEDICAL DEVICES · USA
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?